Graphene stocks
Archer Materials Limited (ASX: AXE) achieved a significant technical milestone on September 10, 2026, completing the initial testing phase for its graphene--based Biochip. The results confirmed the detection of protein biomarkers at concentrations 100 times lower than current industry standards, validating the sensitivity of its proprietary gFET (graphene field--effect transistor) technology. This development facilitates potential entry into the early--stage disease diagnosis market. The company has commenced preliminary discussions with Tier--1 diagnostic providers and is scheduled to present the full data set at the Global MedTech Summit in Singapore on November 5, 2026.